Company Filing History:
Years Active: 2000-2011
Title: Gregory Biesecker: Innovator in Nucleic Acid Ligands
Introduction
Gregory Biesecker is a notable inventor based in Boulder, CO (US). He has made significant contributions to the field of biotechnology, particularly in the development of high-affinity nucleic acid ligands. With a total of 5 patents to his name, Biesecker's work has the potential to impact various medical applications.
Latest Patents
Biesecker's latest patents include innovative methods for identifying and preparing high-affinity nucleic acid ligands to complement system proteins. His work specifically addresses proteins C1q, C3, and C5, utilizing the SELEX method to identify specific RNA ligands. Additionally, he has developed a method for generating blended nucleic acid ligands that incorporate non-nucleic acid functional units. This includes a SELEX-identified RNA ligand to the integrin gpIIbIIIa, which is conjugated to a specific peptide, demonstrating high specificity in inhibiting biological activity. Another significant invention is a single-stranded DNA ligand to elastase, which is coupled to a specific chemical compound, effectively inhibiting elastase's biological activity.
Career Highlights
Throughout his career, Gregory Biesecker has worked with prominent companies in the pharmaceutical and biotechnology sectors. Notable organizations include Gilead Sciences, Inc. and Nexstar Pharmaceuticals, Inc. His experience in these companies has contributed to his expertise in the field and has facilitated his innovative research.
Collaborations
Biesecker has collaborated with esteemed colleagues, including Larry M Gold and Sumeda Jayasena. These partnerships have likely enriched his research and contributed to the advancements in his patented technologies.
Conclusion
Gregory Biesecker's contributions to the field of biotechnology through his patents and collaborations highlight his role as an innovator in nucleic acid ligands. His work continues to pave the way for advancements in medical applications and therapeutic solutions.